Navigation Links
Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Aria's Technology
Date:1/26/2012

SAN JOSE, Calif., Jan. 26, 2012 /PRNewswire/ -- Aria Diagnostics, a molecular diagnostics company, today announced the publication of an independent blinded study that examines the accuracy of its non-invasive prenatal test for the detection of Trisomy 21 (associated with Down syndrome) and Trisomy 18 (associated with Edwards syndrome). The study showed that the test, coupled with a proprietary algorithm to assess individualized risk for these trisomies, distinguished 100 percent of T21 and 98 percent of T18 cases, while correctly identifying 100 percent of the non-trisomic samples. The data appear online in the American Journal of Obstetrics & Gynecology at http://www.sciencedirect.com/science/article/pii/S0002937812000609?v=s5.

(Logo: http://photos.prnewswire.com/prnh/20120109/NY31734LOGO )

"This constitutes a major breakthrough in the non-invasive detection of the two most common trisomies," said Professor Kypros Nicolaides, MD, of Harris Birthright Research Centre for Fetal Medicine at King's College Hospital in the United Kingdom and lead author of the paper. "I am now certain that this test will become a universal screening tool for Trisomies 21 and 18, provided the cost becomes comparable to that of current methods of sonographic and biochemical testing."

The study, titled, "Chromosome-Selective Sequencing of Maternal Plasma Cell-Free DNA for First-Trimester Detection of Trisomy 21 and Trisomy 18" was independently conducted and supported by a grant from the Fetal Medicine Foundation. The study assessed the ability of Aria's highly multiplexed assay, known as Digital Analysis of Selected Regions (DANSR™), to detect T21 and T18 by using chromosome-selective sequencing and to calculate risk scores with the proprietary Fetal-fraction Optimized Risk of Trisomy Evaluation (FORTE™) algorithm in 400 pregnant women at 11 to 13 weeks gestation. In addition to demonstrating the accuracy of Aria's technology, researchers reported that chromosome-selective sequencing requires 10 times less DNA sequencing than massively parallel shotgun sequencing (MPSS) approaches.

"This study provides firm support that Aria's technology has the potential to transform prenatal trisomy testing. Current prenatal testing involves a myriad of options that are confusing and either lack accuracy or pose harm to the pregnant woman and fetus," said Ken Song, chief executive officer of Aria Diagnostics. "We are developing a test that can greatly simplify the standard of care for pregnant women and give providers and patients confidence as a result of our highly accurate results."

About Aria Diagnostics (formerly Tandem Diagnostics)

Aria Diagnostics, Inc., is a molecular diagnostics company committed to providing safe, highly accurate and affordable prenatal tests for maternal and fetal health. Led by an experienced team, Aria is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. Aria's simple blood test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety.

The company began operations in 2010 and is headquartered in San Jose, Calif. For more information, visit www.ariadx.com.


'/>"/>
SOURCE Aria Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unity Management Group Subsidiary Announces First Contracts of 2012 with Purdue Pharma L.P. and Novartis
2. Auxilium Pharmaceuticals, Inc. Announces First Patients Dosed in XIAFLEX® Phase Ib Cellulite Study
3. Interventional Spine, Inc. Announces FDA Clearance of its Opticage™ Expandable Interbody for Treatment of Degenerative Disc Disease
4. Chimerix Announces Presentation of Final Data from CMX001 Phase 2 Trial in Prophylaxis of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients
5. PuraMed BioScience, Inc. Announces LipiGesic®M, Their Unique Migraine Treatment, is Now Available for Purchase at CVS, the 2nd Largest Drug Chain in the United States
6. Integware Announces Systems Integrator Agreement With Siemens PLM Software
7. Millennium Research Institute Announces 2012 Educational Initiatives
8. Tris Pharma Announces Appointment of Dr. Mahdi Fawzi as Top R&D Executive
9. Jazz Pharmaceuticals plc Announces New Executive Appointments
10. BD Announces Webcast of Annual Meeting of Shareholders
11. Codexis Announces CFO Departure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... America Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, ... Segment Forecasts, 2014 - 2025" report to their offering. ... The Latin American ... 21.0 billion by 2025 Low drug registration cost ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
Breaking Medicine Technology:
(Date:4/21/2017)... , ... April 21, 2017 , ... Providing broad access ... in opposition, but there is a better way to address this problem. , That ... of Pharmacy, Public Policy and Economics at the University of Southern California, who served ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, ... of osteoma. An osteoma is a benign bony lump located on the forehead usually ... can cause difficulties with sight and pain. Dr. Shah has discovered an approach that ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... Allegheny County that offers services to communities throughout the greater Pittsburgh metropolitan region, ... charity drive to provide adaptive bicycles for differently-abled children. , Variety the Children’s ...
(Date:4/21/2017)... ... , ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, ... Patient Advocacy Award in recognition of her extraordinary contributions to the field of ... The Beryl Institute’s annual Patient Experience Conference on March 20 in Denver, ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... partnered with O2X , an active lifestyle company that provides Human Performance ... health of firefighters, police offers, first responders, military officers and others in service ...
Breaking Medicine News(10 mins):